Log in

LON:CLLCello Health Share Price, Forecast & News

GBX 112.25
-0.75 (-0.66 %)
(As of 05/26/2020 06:26 AM ET)
Add
Compare
Today's Range
112.25
Now: GBX 112.25
112.25
50-Day Range
110
MA: GBX 115.17
122.50
52-Week Range
100
Now: GBX 112.25
150
Volume884 shs
Average Volume46,452 shs
Market Capitalization£119.76 million
P/E RatioN/A
Dividend Yield1.82%
BetaN/A
Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients. The Cello Signal segment provides market research and direct communications services principally to consumer-facing clients. Cello Health plc was incorporated in 2004 and is headquartered in London, the United Kingdom.
Read More
Cello Health logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.0Community Rank: 3.4Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Marketing Services
Sub-IndustryN/A
SectorServices
CUSIPN/A
CIKN/A
Phone+44-20-78128460

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£166.77 million
Cash FlowGBX 7.74 per share
Book ValueGBX 77.60 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap£119.76 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CLL News and Ratings via Email

Sign-up to receive the latest news and ratings for CLL and its competitors with MarketBeat's FREE daily newsletter.

Cello Health (LON:CLL) Frequently Asked Questions

How has Cello Health's stock been impacted by COVID-19 (Coronavirus)?

Cello Health's stock was trading at GBX 126 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLL shares have decreased by 10.9% and is now trading at GBX 112.25. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cello Health?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cello Health in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cello Health.

How often does Cello Health pay dividends? What is the dividend yield for Cello Health?

Cello Health announced a dividend on Wednesday, March 18th. Shareholders of record on Thursday, April 23rd will be paid a dividend of GBX 2.95 per share on Friday, May 22nd. This represents a yield of 2.85%. The ex-dividend date is Thursday, April 23rd. This is an increase from Cello Health's previous dividend of GBX 1.15. The official announcement can be viewed at this link. View Cello Health's dividend history.

What price target have analysts set for CLL?

1 brokerages have issued 12-month price targets for Cello Health's shares. Their forecasts range from GBX 120 to GBX 160. On average, they anticipate Cello Health's stock price to reach GBX 140 in the next year. This suggests a possible upside of 24.7% from the stock's current price. View analysts' price targets for Cello Health.

Has Cello Health been receiving favorable news coverage?

Media stories about CLL stock have trended very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cello Health earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutCello Health.

Who are some of Cello Health's key competitors?

What other stocks do shareholders of Cello Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cello Health investors own include Lloyds Banking Group (LLOY), Sirius Minerals (SXX), Saga (SAGA), QinetiQ Group (QQ), Optimer Pharmaceuticals (OPTR), Modern Water (MWG), IGAS Energy (IGAS), ICAP (IAP), Gilead Sciences (GILD) and easyJet (EZJ).

Who are Cello Health's key executives?

Cello Health's management team includes the following people:
  • Mr. Mark Scott, CEO & Exec. Director (Age 53)
  • Mr. Mark Bentley, Group Fin. Director, Company Sec. & Exec. Director (Age 48)
  • Mr. Stephen Highley, Group COO & Director
  • Mr. Owen Williams, Managing Partner
  • Mr. Vincent Nolan, Managing Partner

What is Cello Health's stock symbol?

Cello Health trades on the London Stock Exchange (LON) under the ticker symbol "CLL."

How do I buy shares of Cello Health?

Shares of CLL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Cello Health's stock price today?

One share of CLL stock can currently be purchased for approximately GBX 112.25.

How big of a company is Cello Health?

Cello Health has a market capitalization of £119.76 million and generates £166.77 million in revenue each year.

What is Cello Health's official website?

The official website for Cello Health is www.cellogroup.com.

How can I contact Cello Health?

Cello Health's mailing address is 11-13 Charterhouse Buildings, LONDON, EC1M 7AP, United Kingdom. The company can be reached via phone at +44-20-78128460.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.